

Actuality Announces Radiation Oncology Dream Team

Top Radiation Oncologists Collaborate to Reduce Prostate Cancer Therapy Side Effects

BEDFORD, MA – November 1, 2007 – Actuality Medical, Inc., a leading innovator in Dynamic Adaptive Therapy, today announced the formation of its Oncology Advisory Board including members from: Memorial Sloan-Kettering, Harvard/Beth Israel Deaconess Medical Center, Washington University, Texas Cancer Clinic, and Rush Medical Center.

Bradley R. Prestidge, M.D., CEO and Chief Medical Officer, Texas Cancer Clinic, San Antonio, TX. Dr. Prestidge is the founder, President, CEO, and Medical Director of the Texas Cancer Clinic and Texas Prostate Institute - the largest prostate seed implant program in Texas and the remaining South Central United States. Dr. Prestidge is an international expert and was the consultant to the Surgeon General for five years. The author of more than 50 peer reviewed journal articles, he sits on editorial boards of several journals, is an educator for prostate brachytherapy at ASTRO and RSNA and teaches courses in advanced prostate seed implantation. He trained at Stanford University and is board certified in Radiation Oncology.

Jeff M. Michalski, M.D., M.B.A., Professor and Clinical Director, Radiation Oncology, Washington University School of Medicine / Siteman Cancer Center, St. Louis, MO. Dr. Michalski specializes in genitourinary and pediatric oncology and conducts clinical research on the use of radiation therapy for treatment of prostate and other cancers. He is well-published in prostate cancer, as well as image guided therapy, conformal therapy, and alternate prostate treatment. He earned his MD from Medical College of Wisconsin and did his residency at Columbia-Presbyterian Medical Center and Mallinckrodt Institute of Radiology-Washington University School of Medicine. He is board certified in Radiation Oncology.

Dr. Michael J. Zelefsky, MD, Professor of Radiation Oncology, Chief, Brachytherapy Service, Memorial Sloan-Kettering Cancer Center, New York, NY. Dr. Zelefsky is an internationally recognized radiation oncologist with expertise in prostate cancer. He has coauthored more than 150 papers on radiation oncology and prostate brachytherapy, concentrating on real-time intraoperative planning and dynamic dosimetry, patient outcomes and quality of life, and defining the permissible radiation doses for organs near the prostate. He has edited the reference book on brachytherapy and is Editor-in-chief of the journal *Brachytherapy*. His work has shown that higher cure rates can be achieved with the safe delivery of unprecedented high doses of radiation. In collaboration with colleagues from the Center's Medical Physics Department, he is implementing sophisticated, innovative techniques in brachytherapy for prostate cancer, breast cancer, soft-tissue sarcoma, and head and neck malignancies. Dr. Zelefsky earned his MD degree at Albert Einstein College of Medicine and did his residency in Radiation Oncology at Memorial Sloan-Kettering Cancer Center. He is board certified in Radiation Oncology.

Dr. Irving Kaplan, MD, Assistant Professor of Radiation Oncology at Beth Israel Deaconess Medical Center at Harvard Medical School, Boston, MA. Dr. Kaplan's focus

and research on prostate cancer spans more than more than twenty years. His research and publications have centered on techniques and technologies to improve morbidity, accuracy, and quality of brachytherapy. Dr. Kaplan has four U.S. patents and 33 peer-reviewed papers, with eight specifically on prostate brachytherapy, concentrating on intraoperative treatment planning, seed finding and localization error, and CT and MR image guidance. He earned his MD degree from Stanford University, where he also did his residency. He is board certified in Radiation Oncology.

James Chu, Ph.D., FACR, FAAPM, Chief of Radiation Physics, Rush Memorial Hospital, Professor, Rush Medical College, Chicago, IL. Dr. Chu is currently serving as a professor in radiation oncology and medical physics at Rush Medical College in Chicago. Prior to this position, Dr. Chu held various radiation physics professorial and faculty positions at the University of Pennsylvania School of Medicine (Philadelphia); the Health Physics Society (Philadelphia); and the University of Texas, in Arlington, working for the department of physics. Dr. Chu's many accomplishments have been recognized with numerous awards and honors, such as being listed in the "Who's Who in Science and Engineering" from the years 1993-2001 as well as acknowledgement in 2000 in a list of "Outstanding Scientists in the 20th Century." He has 38 technical papers covering dosimetry, treatment planning, information display, and clinical effects of radiation.

Edward J. Holupka, PhD, Director of Medical Physics, Beth Israel Deaconess Medical Center, Assistant Professor at Harvard Medical School, Boston, MA. Dr. Holupka is considered one of the most inventive physicists in radiation oncology. As one of the early technologists in radiation planning software, he developed novel radiation treatment technology including treatment planning, image fusion software, and treatment protocols which are now used by leading medical software companies including CMS. He has four patents related to image guidance and virtual reality for surgical procedures and 15 papers covering seed finding, real-time dosimetry, and seed placement precision. He received his PhD in physics from Brown University.

Amir Sadeghi, Ph.D., Chief of Medical Physics, Texas Cancer Clinic. Dr. Sadeghi is the Chief of Medical Physics at the Texas Cancer Clinic. Dr. Sadeghi oversees the physicists, medical dosimetrists, and graduate students. He is in charge of the radiation treatment planning for MammoSite® patients. He is also an assistant professor of the radiological sciences division of the Department of Radiology at the University of Texas Health Science Center (San Antonio). His professional experience includes over 12 years of research, training, consulting, and treatment planning in radiological physics. Dr. Sadeghi received a bachelor's degree from Louisiana State University in 1984 and a masters of science in medical physics from the University of Texas Health Science Center at San Antonio in 1994 where he also completed his Ph.D. in radiological sciences in 1996. He has 27 technical papers covering prostate dosimetry, dose evaluation, and positioning accuracy.

About Actuality Medical

Actuality is an early-stage medical device company developing and commercializing a novel system used to improve the precision, morbidity, and quality of radiation therapy and surgical excision - initially in prostate and breast cancer. Actuality's initial product, PerspectaSeed 4D, applies Dynamic Adaptive Planning and Therapy in the treatment of prostate cancer using brachytherapy. The Company believes that this product will reduce patient morbidity by enabling a level of precision, certainty, and efficiency previously unattainable in brachytherapy applications. Reducing morbidity positions brachytherapy as the only mainstream, outpatient, single treatment, low cost, low morbidity procedure for prostate cancer. This translates into higher profitability for the hospital, and improved long term quality of life for the patient. The company will pursue a clearance under 510(k) based on five well established predicate devices. The company's addressable market of thirty indications is valued in excess of \$4 billion. Recent exits in this market space include: Tomotherapy [NASDAQ:TTPY], Intuitive Surgical [NASDAQ:ISRG], and Hansen Medical [NASDAQ: HNSN].

Disclaimers, Trademarks

Actuality is a registered trademark of Actuality Systems, Inc. in the United States. MammoSite is a registered trademark of Cytac Corporation. The above claims are not FDA-approved; the technologies described here may not be used to prevent, diagnose, treat, or cure disease.

Media Contact Info:

Michael Goldstein, Actuality Medical, +1 (781) 541-6036 x101.

mgoldstein [at] actuality-medical.com

Gregg Favalora, Actuality Medical, +1 (781) 541-6036 x102.

favalora [at] actuality-medical.com